Moderna saw its stock surge 13% after Oppenheimer & Co. analyst Hartaj Singh upgraded the stock to 'outperform' and predicted five product approvals by 2026.
Despite COVID-19 vaccine sales being their current revenue driver, the company's future hinges on its diverse pipeline of new products.
[
Collection
]
[
|
...
]